TREATMENT OPTIONS FOR LOCALIZED PROSTATE-CANCER BASED ON PRETREATMENTSERUM PROSTATE-SPECIFIC ANTIGEN LEVELS

Citation
Fa. Vicini et al., TREATMENT OPTIONS FOR LOCALIZED PROSTATE-CANCER BASED ON PRETREATMENTSERUM PROSTATE-SPECIFIC ANTIGEN LEVELS, The Journal of urology, 158(2), 1997, pp. 319-325
Citations number
79
Categorie Soggetti
Urology & Nephrology
Journal title
ISSN journal
00225347
Volume
158
Issue
2
Year of publication
1997
Pages
319 - 325
Database
ISI
SICI code
0022-5347(1997)158:2<319:TOFLPB>2.0.ZU;2-T
Abstract
Purpose: We reviewed all available literature on early stage prostate cancer treatment in which pretreatment serum prostate specific antigen (PSA) levels were used to stratify patients. We determined if any con clusions could be reached regarding the optimal therapy of this diseas e. Materials and Methods: A MEDLINE search was conducted to obtain all articles in English on prostate cancer treatment from 1986 to 1996 in which PSA levels were used to stratify patients and evaluate outcome, Studies were considered eligible only if they met all criteria of pre treatment PSA values recorded and grouped for subsequent evaluation, p osttreatment PSA values monitored continuously, definitions of biochem ical control stated and median followup given. Results: Of the 16 surg ical studies identified only 3 met the inclusion criteria, Of the 30 r adiation therapy articles identified 15 met the inclusion criteria, in cluding 2 on conformal external beam radiotherapy, 8 on conventional e xternal beam radiotherapy and 5 on interstitial brachytherapy. No stud ies using neutrons or combined hormonal therapy with surgery or radiot herapy were identified in which patients were stratified by pretreatme nt PSA. Results for all therapies were extremely variable with the 3 t o 5-year rates of biochemical control ranging from 48 to 100% for pati ents with a pretreatment PSA of less than 4 ng./ml., 44 to 90% for PSA more than 4 to 10 ng./ml. and 27 to 89% for PSA more than 10 to 20 ng ./ml, Even using the same treatment modality, a wide range of results were obtained, No treatment option consistently produced superior resu lts. Conclusions: When data were reviewed from studies using pretreatm ent serum PSA to stratify patients, no consistently superior treatment option in the radiotherapy or surgical literature emerged. These data suggest that standard definitions of disease stage and biochemical cu re must be adopted to evaluate treatment efficacy and advise patients on the most appropriate treatment option for the disease.